clinical trial · NCT06882785
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
Bristol-Myers Squibb·phase3·recruiting·n = 250
SchizophreniaKarXTPlacebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of KarXT in acutely psychotic Japanese adult participants with schizophrenia
started
Jun 10, 2025
primary completion
Sep 23, 2028
completion
Aug 23, 2029
last updated
Jun 30, 2026
official title
A Phase 3, Randomized, Two-part Study With a 5-week Double-blind Part (Randomized, Parallelgroup, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol